Promoter mutations associated with hereditary persistence of fetal haemoglobin either disrupt repressors or create de novo sites for activators

ESH eLearning, Merlin Crossley, 265279

Managing CML in emerging regions: some problems and perspectives

ESH eLearning, Hemant Malhotra, 234664

Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors

ESH eLearning, Mauricette Michallet, 234801

The technical decline in the rate of CML treatment-free remission in aging countries: the French experience

ESH eLearning, Marc Delord, 257017

Prevalence and outcomes of uncommon BCR-ABL fusion transcripts in patients with CML: data from a single center

ESH eLearning, Qian Jiang, 257018

Aim for the cure: TKI-based chemotherapy for Ph+ ALL

ESH eLearning, Elias Jabbour, 257019

Patients' perspectives on the definition of cure in chronic myeloid leukemia: a US based survey

ESH eLearning, Gemlyn George, 257030

Long-term results of a phase 2 trial of nilotinib 400 Mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia

ESH eLearning, Lucia Masarova, 257031

Treatment-free remission in patients with chronic phase chronic myeloid leukemia and stable deep molecular response discontinuing dasatinib (DASFREE)

ESH eLearning, Susanne Saussele, 257032

Low-intensity TKI-based therapy for Ph+ ALL

ESH eLearning, Hervé Dombret, 234568

Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective

ESH eLearning, Shinto Francis Thekkudan, 234569

Are TKI really safe?

ESH eLearning, C Gambacorti, 234570

Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study

ESH eLearning, Young Rok Do, 234571

Molecular milestones using the BCR-ABL1 qPCR level and doubling time after imatinib discontinuation to predict successful treatment-free remission: treatment-free remission accomplished by dasatinib (TRAD) trial

ESH eLearning, Dennis KIM, 234573

Stem cell transplant for Ph+ ALL: who, when, how

ESH eLearning, Federico Lussana, 234797

How to identify and manage Ph-like ALL

ESH eLearning, Sarah Tasian, 234798

What prevents the disease from relapsing after TKI discontinuation

ESH eLearning, Satu Mustjoki, 234803

Loss of function of the SETD2 tumor suppressor is a recurrent event in advanced-phase chronic myeloid leukemia, is due to post-translational mechanisms and fosters genetic instability

ESH eLearning, Manuela Mancini, 257025

MDS/MPN: SENECTUS IPSA EST MORBUS?

ESH eLearning, Michael Deininger, 257026

CML hematopoietic stem cells expressing IL-1RAP may be targets of chimeric antigen receptor (CAR) - engineered T-cells

ESH eLearning, Christophe Ferrand, 257027

A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies common drug resistance mechanisms 

ESH eLearning, Matthieu Lewis, 257028

Modulation of p53 with the MDM2 antagonist idasanutlin, in combination with nilotinib treatment, targets primitive CML cells in vitro and in vivo.

ESH eLearning, David Vetrie, 257029

ELN and real-word treatment algorithms for MPNs

ESH eLearning, Giuseppe Saglio, 234566

The association of transposable elements with chronic myeloid leukemia supports an assumption that non-coding variable regions of the human genome may play a role in hematological malignancies

ESH eLearning, Jitka Koblihova, 234567

HMGCLL1 Is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

ESH eLearning, Dennis KIM, 234572

Bcl-2 and its inhibition in leukemia

ESH eLearning, Marina Konopleva, 234637

Novel approaches to monitor MPN

ESH eLearning, Jerry Radich, 234799

Resistance and progression to TKI: not just mutations

ESH eLearning, Jerry Radich, 234800

Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias

ESH eLearning, Justin Pritchard, 234802

Nilotinib vs. Nilotinib plus interferon α induction and nilotinib or interferon α maintenance therapy for newly diagnosed BCR-ABL positive. Chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V) trial

ESH eLearning, Andreas Hochhaus, 257020

Spirit 2: final analysis of an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML

ESH eLearning, Stephen OBrien, 257021

TNFα-induced bone marrow stromal niche alterations enhance leukemic stem cell growth via CXCL1/CXCR2 signaling

ESH eLearning, Puneet Agarwal, 257022

Identification of metabolic vulnerabilities in leukemic stem cells using the integrative omic approach 

ESH eLearning, Zuzana Brabcova, 257023

Minimal, measurable, atypical

ESH eLearning, Nick Cross, 257024

Why the fuss over CML stem cells ?

ESH eLearning, Robert Peter Gale, 234565

Mastocytosis

ESH eLearning, Jason Gotlib, 219417

Are we using personalized treatment for patients with myelofibrosis?

ESH eLearning, Alessandro Vannucchi, 219254

Epigenetics in myeloproliferative neoplasms

ESH eLearning, Mary-Frances McMullin, 219251

Dissecting the molecular genetics of MPN

ESH eLearning, Ann Mullally, 219252

Stem cell depletion therapy is needed to change the natural history of the MPNs

ESH eLearning, Ronald Hoffman, 219253

Somatic mutations and clonal relationships

ESH eLearning, Peter Campbell, 219247

MPN Drivers: from active JAK2 and TpoR mutants to rogue calreticulin and their role in progression

ESH eLearning, Stefan N Constantinescu, 219248

Role of epigenetic dysregulation in MPN pathogenesis

ESH eLearning, Ross L. Levine, 219249

Megakaryocyte differentiation therapy in the MPNs

ESH eLearning, John D. Crispino, 219250

Antibodies & antibody conjugates

ESH eLearning, Wendy Stock, 219267

CAR T-cells

ESH eLearning, Noëlle Frey, 219268

Treatment of poor ELN risk AML

ESH eLearning, Richard Schlenk, 219258

Salvage therapy

ESH eLearning, Arnold Ganser, 219259

FLT3 inhibitors

ESH eLearning, M Levis, 219260

IDH inhibitors

ESH eLearning, Eytan Stein, 219261

Therapy of acute promyelocytic leukemia

ESH eLearning, Lionel Adès, 219262

Gemtuzumab Ozogamicin

ESH eLearning, Alan Burnett, 219263

Maintenance therapy after transplantation

ESH eLearning, Charles Craddock, 219264

Low-intensity treatments

ESH eLearning, Hervé Dombret, 219265

Tumor target antigens in AML

ESH eLearning, Marion Subklewe, 219266

Diagnosis of ph-like ALL

ESH eLearning, Charles Mullighan, 219255

Leukemic stem cells modulate the bone marrow microenvironment

ESH eLearning, Bonnet Dominique, 219256

Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No

ESH eLearning, Farhad Ravandi-Kashani, 219257

Understanding gene-gene interactions via machine learning: Pandora’s box?

ESH eLearning, Andrew Wei, 226246

Improving the activity of BH3 mimetic venetoclax: a case study

ESH eLearning, Andrew Wei, 226247

Clinical trials investigating venetoclax combinations for AML

ESH eLearning, Andrew Wei, 226248

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias

ESH eLearning, Arnold Ganser, 226249

The devastating effects of relapsed or refractory AML

ESH eLearning, Arnold Ganser, 226250

From bench to the bedside: understanding the genetic changes in AML

ESH eLearning, Arnold Ganser, 226251

Finding the right targets for CAR T-cell therapy in AML

ESH eLearning, Arnold Ganser, 226252

Midostaurin: the first drug to receive approval for AML since 2000

ESH eLearning, Arnold Ganser, 226253

Overcoming the issues with clinical trial recruitment

ESH eLearning, Arnold Ganser, 226254

Transplantation clinical trial network to build available prospective studies on AML

ESH eLearning, Charles Craddock, 226255

Current understandings of ALL approaches

ESH eLearning, Charles Craddock, 226256

Challenges with the identification of ALL subtypes

ESH eLearning, Charles Craddock, 226257

Improving response to ALL therapies

ESH eLearning, Charles Craddock, 226258

Minimal residual disease: a key determinant of ALL treatment response

ESH eLearning, Charles Craddock, 226259

Increasing the effectiveness of ALL therapies

ESH eLearning, Charles Craddock, 226260

Combination therapy for the treatment of AML

ESH eLearning, Christoph Röllig, 226261

Applying the right therapies to the right AML patient population

ESH eLearning, Christoph Röllig, 226262

MRD detection techniques in AML: pros and cons

ESH eLearning, Christoph Röllig, 226263

Immunotherapies for the treatment of AML

ESH eLearning, Christoph Röllig, 226264

Managing AML in elderly patients

ESH eLearning, Christoph Röllig, 226265

Biological rationales when determining AML therapies

ESH eLearning, Christoph Röllig, 226266

Targeting IDH mutations for the treatment of AML

ESH eLearning, Eytan Stein, 226267

Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

ESH eLearning, Eytan Stein, 226268

Primary and secondary resistance in AML

ESH eLearning, Eytan Stein, 226269

Encouraging patients to participate in AML trials

ESH eLearning, Eytan Stein, 226270

The latest clinical trials into novel AML therapies

ESH eLearning, Eytan Stein, 226271

The complications of treating elderly patients with AML

ESH eLearning, Gail Roboz, 226272

Managing relapse in AML: the role of MRD

ESH eLearning, Gail Roboz, 226273

Combining existing drugs for the creation of novel AML therapies

ESH eLearning, Gail Roboz, 226274

Increasing AML clinical trial participation rates

ESH eLearning, Gail Roboz, 226275

The challenges of choosing the right target antigen in AML compared to ALL

ESH eLearning, Marion Subklewe, 226276

Exciting immunotherapy clinical trials for the management of AML

ESH eLearning, Marion Subklewe, 226277

How can we improve CAR T-cell therapy?

ESH eLearning, Marion Subklewe, 226278

Immunotherapy clinical trial participation in R/R AML

ESH eLearning, Marion Subklewe, 226279

Involving the patient is a key part of cancer treatment

ESH eLearning, Mark Levis, 226280

CAR T-cell therapy and ALL: the current landscape

ESH eLearning, Noelle Frey, 226281

The CAR T-cell therapy race

ESH eLearning, Noelle Frey, 226282

The importance of MRD assessment in all phases of ALL treatment

ESH eLearning, Noelle Frey, 226283

Next-generation methodologies: the future for MRD monitoring in ALL?

ESH eLearning, Wendy Stock, 226284

Emerging novel approaches for ALL: inotuzumab ozogamicin

ESH eLearning, Wendy Stock, 226285

Support systems are a crucial factor in ALL treatment

ESH eLearning, Wendy Stock, 226286

Bone marrow transplant in red cell disorders

ESH eLearning, eliane Gluckman, 219043